Merck’s Mevacor Switch Bid Digs Deeper Into Consumers’ Self-Selection
This article was originally published in The Tan Sheet
Executive Summary
Merck's self-selection study developed to support its latest Mevacor OTC switch application will bolster its bid by providing deeper insight into consumers' selection decisions, the firm says
You may also be interested in...
FDA Expects OTC Switch Self-Selection Studies To Probe Consumer Thinking
A draft guidance on designing self-selection studies in support of Rx-to-OTC switches reflects FDA’s interest in drilling down for greater insight into consumers’ thought processes.
Crestor Indication Grows User Pool, But Self-Selection Hinders Statin Switch
Switching statins OTC will require comprehensive consumer education to enable self-selection and flexibility from FDA on the types of information it considers product labeling
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
More information from "real world" experiences on how consumers make OTC selections may be needed to pull off a successful Rx-to-OTC switch of a statin